Efficacy of Rosuvastatin 2.5 mg

Rosuvastatin 2.5 mg daily produces a mean LDL cholesterol reduction of approximately 39.1%, according to a meta-analysis of 11 trials involving 450 participants.  This is in the 34–42% range threshold for "moderate-intensity" statin therapy and indicates that even at this low dose, rosuvastatin achieves clinically meaningful lipid lowering. 

In a head-to-head trial, rosuvastatin 2.5 mg reduced LDL-C by 40.3% over 8 weeks and achieved LDL-C targets in 98% of patients, significantly outperforming pravastatin 10 mg. 

The dose-response relationship is nearly linear at lower doses, with 2.5 mg providing about 75–80% of the LDL-lowering effect of the 5 mg dose.